ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at HC Wainwright

Posted by Doug Madison on May 2nd, 2024

Stock analysts at HC Wainwright started coverage on shares of ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $25.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 49.79% from the stock’s previous close.

Several other research analysts have also issued reports on the company. Jefferies Financial Group initiated coverage on ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $35.00 target price for the company. The Goldman Sachs Group initiated coverage on ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $27.00 target price for the company. Finally, Citigroup initiated coverage on ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $30.00 target price for the company.

Read Our Latest Analysis on AVBP

ArriVent BioPharma Trading Up 1.0 %

Shares of NASDAQ AVBP opened at $16.69 on Tuesday. The stock’s 50 day moving average is $18.12. ArriVent BioPharma has a 1-year low of $14.35 and a 1-year high of $25.95.

Institutional Trading of ArriVent BioPharma

A hedge fund recently bought a new stake in ArriVent BioPharma stock. BNP Paribas Financial Markets purchased a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,659 shares of the company’s stock, valued at approximately $83,000. 9.48% of the stock is currently owned by institutional investors and hedge funds.

About ArriVent BioPharma

(Get Free Report)

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.